Artelo Biosciences
ARTL
6 hedge funds and large institutions have $220K invested in Artelo Biosciences in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
191% more capital invested
Capital invested by funds: $75.8K → $220K (+$144K)
0.86% more ownership
Funds ownership: 0.15% → 1.01% (+0.86%)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$71.3K |
| 2 |
Citigroup
New York
|
+$55 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$12.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.26K |
| 5 |
RIL
Rothschild Investment LLC
Chicago,
Illinois
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $213K | +$71.3K | +3,857 | +259% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $5.93K | -$1.26K | -68 | -31% |
|
|
3
UBS Group
Zurich,
Switzerland
| $1.18K | -$12.6K | -680 | -96% |
|
|
4
Citigroup
New York
| $119 | +$55 | +3 | New |
|
5
Bank of America
Charlotte,
North Carolina
| $66 | – | – | – |
|
6
Morgan Stanley
New York
| $53 | – | – | – |
|
|
DB
7
Danske Bank
Copenhagen K,
Denmark
| $13 | – | – | – |
|
8
Fidelity Investments
Boston,
Massachusetts
| $13 | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$19.9K | -1,261 | Closed |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$17.8K | -1,133 | Closed |
|
|
RIL
11
Rothschild Investment LLC
Chicago,
Illinois
| – | -$7 | – | – |
|
ARTL Hedge Fund Activity: Q2 2025 in Review
6 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q2 2025, worth a combined $220K — up 191% from $75.8K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ARTL and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Geode Capital Management, adding an estimated $71.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $19.9K sold.
- 6 institutional investors held Artelo Biosciences (ARTL) as of Q2 2025, down from 7 in Q1 2025.
- Funds reported $220K of Artelo Biosciences stock for Q2 2025, up 191% quarter-over-quarter.
- 1 fund opened new Artelo Biosciences positions in Q2 2025 and 2 closed out, a net change of -1 holder.
- The largest Artelo Biosciences buyer in Q2 2025 was Geode Capital Management, an estimated $71.3K added.
- The largest Artelo Biosciences seller in Q2 2025 was Citadel Advisors, an estimated $19.9K sold.
Based on aggregated 13F filings for Q2 2025.